Wai Chun Bio-Technology (HKG:0660) widened its attributable loss for the year ended June 30 to HK$44.2 million from HK$15.4 million in the year-ago period, a Dec. 20 filing on the Hong Kong bourse stated.

Loss per share was HK$0.258, up from HK$0.091 in the corresponding period of the last fiscal year.

The modified starch and other biochemical product company's revenue fell by 52% to HK$370.1 million in the fiscal year from HK$773.7 million a year prior.

The firm attributed the higher loss mainly to the recognition of impairment losses on non-financial assets in the fiscal year.